The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First relapse in patients with multiple myeloma: Outcomes and predictors.
 
Sukriti Seth
No Relationships to Disclose
 
Prashant Kapoor
Honoraria - Abbvie (Inst); Abbvie (Inst); AstraZeneca; BeiGene; MustangBio; Pharmacyclics; Sanofi (Inst)
Consulting or Advisory Role - Sanofi (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); GlaxoSmithKline (Inst); Ichnos Sciences (Inst); Karyopharm Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Janssen; Sanofi
 
Francis Buadi
No Relationships to Disclose
 
Moritz Binder
No Relationships to Disclose
 
Joselle Cook
Stock and Other Ownership Interests - Geron
 
Angela Dispenzieri
Consulting or Advisory Role - Janssen Research & Development
Research Funding - Alnylam (Inst); Celgene (Inst); Janssen Oncology (Inst); Pfizer (Inst); Prothena; Takeda (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Pfizer; Prothena
 
David Dingli
Consulting or Advisory Role - Alexion Pharmaceuticals; Apellis Pharmaceuticals; Bristol-Myers Squibb; JJ Innovative Medicine; Legend Biotech; Novartis; Sanofi
Research Funding - K36 Therapeutics (Inst)
 
Amie L. Fonder
No Relationships to Disclose
 
Morie A. Gertz
Honoraria - Abbvie; Akcea Therapeutics; Alnylam; Amgen; Apellis Pharmaceuticals; Celgene; Janssen Oncology; Juno/Celgene; Med Learning Group; Prothena; Research to Practice; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Sanofi; Prothena
Travel, Accommodations, Expenses - Celgene; Novartis; Prothena
 
Wilson I. Gonsalves
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Bristol Myers Squibb Foundation (Inst); ORIC Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent number: 10996224: Assessing and treating precursor plasma cell disorders
 
Suzanne R. Hayman
No Relationships to Disclose
 
Lisa Hwa
No Relationships to Disclose
 
Miriam A. Hobbs
No Relationships to Disclose
 
Taxiarchis Kourelis
Research Funding - Novartis
 
Nelson Leung
Stock and Other Ownership Interests - Abbvie; senseonics; Verrica Pharmaceuticals
Research Funding - Omeros
 
Yi Lin
Consulting or Advisory Role - Adicet Bio (Inst); Bristol-Myers Squibb (Inst); Caribou Biosciences (Inst); Chimeric Therapeutics (Inst); Fosun Kite (Inst); Genentech (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Nektar (Inst); NexImmune (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Vineti (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst)
 
Eli Muchtar
No Relationships to Disclose
 
Rahma M. Warsame
No Relationships to Disclose
 
S. Vincent Rajkumar
No Relationships to Disclose
 
Shaji Kumar
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); K36 (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Allogene Therapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); CARsgen Therapeutics (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MedImmune (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Pfizer